Drug Database
ER

erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

✓ Approved

Cinnagen Co · EPOR · 重组蛋白

什么是 erythropoietin beta?

erythropoietin beta 是一种重组蛋白,由Cinnagen Co研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名CinnaPoietin ß, CinnaPoietin
公司Cinnagen Co
药物类别重组蛋白
分子靶点EPOR
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

erythropoietin beta 作用于 1 个分子靶点:

EPORerythropoietin receptor (EPO-R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

erythropoietin beta 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

相关研究文献

PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-19

Roxadustat for treatment of suspected erythropoietin(EPO)-induced pure red cell aplasia in a hemodialysis patient: a case report.

Jiang Sufang S, Zhou Yumei Y, Xie Yunhan Y, Song Shaowei S et al.

Anemia is a prevalent complication in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Recombinant human erythropoietin (rhEPO) is widely administered to patients both on and off dialysis to manage this anemia. However, despite an initial favorable therapeutic response, a sudden and unexplained decline in hemoglobin (Hb) levels often prompts the need for further diagnostic evaluation. In this context, we report a clinical case involving a 48-year-old male patient who had been undergoing hemodialysis (HD) for two years. During the course of his rhEPO treatment regimen, he may have developed pure red cell aplasia (PRCA), a rare but serious adverse reaction. Upon recognition of this complication, the administration of rhEPO was promptly discontinued, and the patient was initiated on roxadustat therapy. Following nine months of continuous roxadustat treatment, the patient experienced a significant and sustained increase in his Hb levels. This clinical outcome underscores the importance of prompt diagnosis and intervention in cases of suspected erythropoietin (EPO)-induced PRCA. Furthermore, our findings suggest that roxadustat may serve as a viable and effective therapeutic option for patients with suspected EPO-induced PRCA, potentially obviating the need for immunosuppressive therapy and its associated risks.

PMID 43052388
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Tricuspid regurgitation is a barrier to guideline-directed medical therapy implementation in patients with acute decompensated heart failure and reduced ejection fraction.

Brollo Enrico E, Cocianni Daniele D, Barbisan Davide D, Perotto Maria M et al.

Guideline-directed medical therapy (GDMT) reduces mortality in heart failure with reduced ejection fraction (HFrEF), but multiple barriers prevent the correct implementation of recommended treatments. We sought to evaluate the role of tricuspid regurgitation (TR) as an obstacle for GDMT implementation in a cohort of HFrEF patients after an episode of acute decompensated heart failure (ADHF). We enrolled patients hospitalized for ADHF with left ventricular ejection fraction (LVEF) ≤ 40%. TR severity was categorized as moderate-severe or trivial-mild. Optimization of renin-angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitors (RASi/ARNi), beta-blockers and mineralocorticoid receptor antagonists (MRA) therapy was defined when patients were prescribed these drugs at ≥50% of the target dose (TD) at 1-year follow-up. 858 patients were enrolled. At 12 months, patients receiving ≥50% TD of RASi/ARNi, beta-blockers and MRA were 51%, 29%, and 47% respectively. After adjustment for multiple confounders, moderate-severe TR was inversely associated with the likelihood of ≥50% TD up-titration of RASi/ARNi (OR = 0.572, P = .029) and of beta-blockers (OR = 0.526, P = .038), but not of MRA (OR = 0.995, P = .984). RASi/ARNi and beta-blockers optimization was associated with lower 1- and 5-years all-cause mortality risk regardless the severity of TR. The association between RASi/ARNi optimization and 5-years survival was more pronounced in patients with moderate-severe TR vs patients with trivial-mild TR (P for int = .039). The severity of TR in ADHF is a determinant of poor implementation of RASi/ARNi and beta-blockers therapy at 1-year follow-up; however, the lower mortality associated with treatment optimization was not influenced by TR severity.

PMID 43053843
阅读全文 →
PubMedBrain injury2026-11-19

Continuous multimodal neuromonitoring of zolpidem-induced paradoxical awakening in chronic incomplete locked-in syndrome: ventral pontine deafferentation, cross-modal complementarity, and cardio-cortical dissociation.

Machado Calixto C, Rodriguez-Rojas Rafael R, Sanchez Jose Jesus JJ, Mualem Raed R

Zolpidem paradoxically restores responsiveness in select disorders of consciousness (DOC) cases, yet real-time electrophysiological and autonomic dynamics across the pharmacodynamic trajectory remain uncharacterized in incomplete locked-in syndrome (LIS). A 52.18-min multimodal recording tracked baseline, enteral zolpidem administration (min 22.39), absorption, corticomotor peak, and plateau in a 42-year-old male with chronic LIS from pontine infarction. Analytics included continuous qEEG (0.5-70 Hz), microstates (Classes A-D), beta-band weighted Phase Lag Index (wPLI) connectomics, heart rate variability (HRV), and heartbeat‑evoked responses (HER). Baseline deafferentation showed severe theta slowing (48.36 ± 4.14%) and phase hypersynchrony. Following enteral administration, the following changes were observed: 1. viscero-cortical dissociation: Infusion triggered an immediate HRV VHF surge (>80%) while the cortex remained quiescent for 14.1 min. 2. Corticomotor consolidation: Between min 36.5-46.0, relative beta surged (+266.89%) while theta dropped (-30.74%). Microstates accelerated into frontocentral Classes C/D, and connectomics demonstrated long-range edge pruning with selective frontocentral recruitment (wPLI > 0.40). 3. Interoceptive gating: During peak beta emergence, cardio-cortical communication collapsed; evoked global variance profile dropped > 60% (1.03 to 0.22 µV) alongside frontocentral dipole suppression. Paradoxical awakening is a coordinated multisystem process. Zolpidem disinhibits spared corticomotor networks while filtering ascending visceral baro-afferents, enabling an outward-facing behavioral state decoupled from internal interoception.

PMID 43052692
阅读全文 →
PubMedBrain and behavior2026-11-19

Tracking Neurophysiological Trajectories in Adolescent Non-Suicidal Self-Injury During Mindfulness-Based Intervention: A Longitudinal Single-Channel EEG Study.

Tong B G BG, He Xuemei X, Ren Rui R, Yu Yuanyuan Y et al.

Adolescent non-suicidal self-injury (NSSI) remains a major clinical challenge, and objective neurophysiological monitoring during early intervention is lacking. This prospective longitudinal observational study characterized longitudinal EEG trajectories during an individualized home-based EEG biofeedback editation (H-EBM) intervention in hospitalized adolescents with NSSI and explored whether neurophysiological trajectory features were associated with emotional improvement. Fifty-two hospitalized adolescents with NSSI (DSM-5 criteria) who received routine inpatient psychiatric care together with daily H-EBM sessions over approximately 10 days were included in the per-protocol analysis. H-EBM integrated metaphor-guided therapeutic narratives with real-time EEG biofeedback via a single-lead device (Fp1, 512 Hz). Emotional states were assessed at admission and discharge using the profile of mood states (POMS). Participants were exploratorily classified into exploratory responder ( n = 36 ) and non-responder ( n = 16 ) subgroups based on total mood disturbance (TMD) improvement. Longitudinal alpha/beta power ratio trajectories were compared between subgroups, and associations between EEG trajectory slopes and TMD improvement were examined. The exploratory responder subgroup showed significant reductions in TMD scores and core symptom subscales (depression and tension; all p < 0.001 ), whereas the exploratory non-responder subgroup showed no improvement. The alpha/beta ratio in the exploratory responder subgroup exhibited a progressive upward trajectory across training sessions, while this ratio remained stable or fluctuated in the exploratory non-responder subgroup. The alpha/beta ratio slope was positively associated with TMD improvement scores (Pearson r = 0.43 , 95% CI [0.18, 0.63], p = 0.002 ). Exploratory logistic regression suggested that the alpha/beta ratio slope was associated with exploratory responder status after adjusting for age and gender (OR = 9.49, 95% CI [1.01, 89.44], p = 0.049 ). Exploratory ROC analysis showed moderate apparent (in-sample) discriminative performance (AUC = 0.774, 95% CI [0.638, 0.899]). Longitudinal neurophysiological trajectories during individualized H-EBM were associated with emotional improvement in hospitalized adolescents with NSSI. These preliminary findings suggest that EEG trajectory analysis may represent a promising objective monitoring approach during individualized mindfulness-based interventions. Given the observational design without a control group, future randomized controlled studies are warranted to examine potential therapeutic effects.

PMID 43053476
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-19

Atypical inflammatory bowel disease and multi-system inflammation expand the phenotype of inhibitor of nuclear factor kappa B kinase subunit beta gain-of-function variants.

Ashton James J JJ, Selby Mercedes M, Green Zachary Z, Win Lynn K LK et al.

Gain-of-function (GoF) variants in the inhibitor of nuclear factor kappa-B kinase subunit beta (IKK2) protein, encoded by inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), have previously been reported to cause autoinflammation with a progressive immunodeficiency. Genetic defects have not previously been described in inflammatory bowel disease (IBD), although disruption of highly interacting proteins, such as IKBKG and RELA, are known causes of monogenic IBD. Using whole exome sequencing data, we screened a cohort of over 1250 adult and paediatric onset patients with IBD for deleterious variants (minor allele frequency < 0.0005, Combined Annotation Dependent Depletion [CADD] > 15) in IKBKB. We retrieved in-depth phenotypic data and performed peripheral blood mononuclear cell CD25/CD70 stimulation validation in patients with apparent IKBKB GoF variants. We identified 11 patients with potentially pathogenic variants. Correlation with clinical and immunophenotypic data prioritised a rare, potential gain-of-function, variant in a patient and his affected parent, c.522T>G, p Asp174Glu. The proband had multi-system inflammation and severe atypical inflammatory bowel disease with rectal stricturing. We demonstrated impaired CD25/CD70 T- and B-cell responses in the patient, characteristic of the IKBKB defect, alongside hallmark immunological manifestations of reduced natural killer and B-cell numbers, and perturbed immunoglobulin titres. Treatment with a selective Janus kinase (JAK1)-inhibitor resulted in rapid clinical and biochemical improvement. This study expands the phenotypic manifestation of IKBKB GoF variants to include IBD and demonstrates a biologically plausible targeted treatment. Further functional work is required to elucidate the precise mechanism of bowel inflammation and identify additional patients.

PMID 43053635
阅读全文 →
PubMedHaematologica2026-11-19

Reduced intensity hematopoietic cell transplant using best available donor and post-transplant cyclophosphamide is safe and curative for transfusion-dependent thalassemia

Ktena Yiouli P YP, Burris Megan M, Berger Rebecca R, Duke Kathryn K et al.

Over 300,000 live births annually are affected by hemoglobinopathies worldwide. Of these, transfusion-dependent thalassemias (TDTs) result in severe phenotypes that significantly impact quality of life, shorten life expectancy, and incur high lifetime healthcare costs driven by recurrent transfusions and chelation therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) is curative but limited by donor availability, regimen toxicity, graft-versus-host disease (GVHD), and transplant-related mortality. We present our single-center experience of TDT patients who underwent allo-HCT using a reduced-intensity conditioning (RIC) regimen (anti-thymocyte globulin, fludarabine, cyclophosphamide, total body irradiation) and posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis. Twenty-five consecutive children and young adults (ages 2-23 years, median 9) with TDT (beta-thalassemia major n=21, hemoglobin E-beta thalassemia n=3, hemoglobin D-beta thalassemia n=1) underwent HCT from July 2013 to November 2024. Bone marrow was the most common graft source (n=23, 92% of all patients), and haploidentical donors were the most common donor type (n=19, 76% of all patients). Neutrophil and platelet recovery occurred at median 21 days (range 13-38) and 26 days (range 16-88), respectively. Five patients (20%) developed grade I-II acute GVHD; none developed grade III-IV acute GVHD. Two (8%) developed mild chronic GVHD. At a median follow-up of 5.6 years (range 0.7-10), 5-year overall survival was 100%, transfusion-free survival 96%, and thalassemia-free-GVHD-free survival 96% - one patient experienced near-complete loss of donor chimerism with return of the TDT phenotype. Our RIC platform with best-available donor and PTCy-based GVHD prophylaxis significantly reduces post-HCT complications while providing durable transfusion independence, offering a proven, accessible, curative option for TDT.

PMID 43053710
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多erythropoietin beta